MedTrace Logo

Hydration Intervention to Decrease Side Effects Associated With GLP - 1 RA Therapy

NCT07641361 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-06-11

No results posted yet for this study

Summary

This is a 17 - week study consisting of a one - week run - in period and a 16 - week intervention. The 16 - week pilot interventions aims to increase hydration in those beginning GLP - 1 RA therapy. Investigators aim to increase hydration to potentially decrease side effect severity, amount of side effects, and drug discontinuation associated with GLP - 1 RA therapy. The investigators are piloting to assess feasibility and preliminary efficacy of the intervention through examining participant retention, participant feedback, researcher and participant adherence to protocols, impact on hydration biomarkers, and participant reported GLP - 1 RA side effects.

Conditions

Interventions

BEHAVIORAL

Hydration Plus

The hydration plus intervention aims to increase hydration through employing the following behavior change strategies/techniques: coaching (consisting of goal setting, making a plan, and coping planning), positive feedback, and utilize a contingency management payment schedule wherein participant earned amount hinges on them meeting their goal.

BEHAVIORAL

Control

Participants randomly assigned to the control group will receive information on hydration and will receive prompts to drink.

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • State University of New York at Buffalo

    lead OTHER

Principal Investigators

  • Katherine N Balantekin, PhD, RD · University at Buffalo

  • Elizabeth G Mietlicki-Baase, PhD · University at Buffalo

  • Leonard H Epstein, PhD · University at Buffalo

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-15
Primary Completion
2027-02-01
Completion
2027-02-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07641361 on ClinicalTrials.gov